WAYNE, N.J., Nov. 3 /PRNewswire/ -- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, announced today that it will celebrate the golden anniversary of its vascular grafts line with an educational event featuring Michael L. Marin, M.D., Professor and Chairman of Surgery at Mt. Sinai Hospital in New York.
Dr. Marin will give a clinical presentation during a dinner for surgeons to be held on November 19 from 6:30-10:30 p.m. EST at the Intrepid Sea Air & Space Museum on the Intrepid aircraft carrier at Pier 96 in New York. Dr. Marin’s presentation, entitled, “A History of Aortic Surgery,” will cover the history of vascular grafts and endovascular devices and how their introduction has fueled advancements in aortic surgery.
“The HEMASHIELD graft legacy dates back to innovation that began in the 1950s with a group of visionary surgeons and continues today,” said Raoul Quintero, President and CEO, MAQUET Cardiovascular U.S. Sales LLC. “From a single vascular graft introduced decades ago, the HEMASHIELD line has grown to include an incomparable array of vascular grafts designed to help surgeons treat patients with narrowed, blocked or dilated arteries. MAQUET is committed to continuing to provide vascular surgeons with innovative and convenient clinical solutions to improve the outcomes of patients with vascular disease, a leading cause of morbidity and mortality worldwide.”
HEMASHIELD grafts, used for surgical repair of aneurysmal and occluded arteries, are the most studied and used vascular products available on the market today. HEMASHIELD grafts have demonstrated clinical efficacy and improved patient outcomes. Published data have shown that they promote natural healing and long-term patency, and that patients benefit from reduced procedure time. More than 2 million HEMASHIELD grafts have been implanted in patients worldwide.
“This Golden Anniversary event celebrates the pioneering surgeons who have pushed the boundaries over the last five decades to deliver new and better life-saving interventions to their patients. This event also affirms MAQUET’s dedication to surgeon education and our partnership with physicians in developing revolutionary vascular graft technology,” said William Friedberg, President, MAQUET Cardiovascular’s Vascular Interventions business unit. “As we enter the sixth decade of vascular grafts, we will continue to build on our 50-year history of innovation and our partnership with our customers as we launch a new family of vascular grafts for peripheral vascular procedures.”
About The MAQUET Group
The MAQUET Group is the global market leader for Medical Systems, focusing on the Operating Room (OR) and Intensive Care Unit (ICU). The integrated products of MAQUET are specially designed to deliver optimal clinical treatment and therapy concepts within acute care hospitals. MAQUET provides innovative medical solutions from three Divisions:
MAQUET is a subsidiary of the publicly-listed Swedish GETINGE GROUP, a company with over $2.8 billion in revenues (2008 fiscal year) and 12,800 employees worldwide. In 2008 MAQUET itself generated pro-forma revenues (including the acquisition of Datascope Corp.) of over $1.4 billion. The company now has 5,000 employees in 34 international sales and service organizations, as well as a network of more than 200 sales representatives.
www.maquet.com
www.getingegroup.com
MAQUET - The Gold Standard.
CONTACT: Philip Freed of MAQUET Cardiovascular LLC, +1-973-709-7514,
Mobile, +1-917-806-8464, philip.freed@maquet.com
Web site: http://www.maquet.com/
http://www.getingegroup.com/
